Who Supplies Hydrochlorothiazide to India from ITALY

Importing finished pharmaceutical formulations containing Hydrochlorothiazide into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. An Import Registration Certificate and Import License must be obtained from CDSCO. For new drugs, approval under Rule 122E is necessary before registration. The application process involves submission to the Licensing Authority under the Act, i.e., the Drugs Controller General (I) at CDSCO.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with Certificates of Analysis (CoA) provided for each batch. Stability data must comply with International Council for Harmonisation (ICH) guidelines, specifically Zone IV, to ensure product stability in India's climate. Products must meet the standards set by the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.

In April 2025, the CDSCO introduced mandatory import registration and licensing for all imported medicines to prevent the sale of unapproved or illegal drugs in the Indian market. This regulation requires that both the drug and the manufacturing site be registered with CDSCO. Additionally, the Production-Linked Incentive (PLI) scheme, implemented in 2020, aims to boost domestic manufacturing and may impact the import of finished pharmaceutical formulations, including those containing Hydrochlorothiazide. The scheme encourages local production, potentially reducing reliance on imports.

India imports finished Hydrochlorothiazide formulations primarily due to the availability of patented or branded products, specific dosage forms not produced domestically, and the need to meet diverse patient requirements. The domestic market for Hydrochlorothiazide formulations is substantial, with a total export market valued at $406.8 million across 403 exporters to 149 countries. This indicates a significant demand for these formulations within India.

Italy's pharmaceutical industry is renowned for high-quality standards, innovative formulations, and adherence to Good Manufacturing Practices (GMP). Italian manufacturers offer patented formulations and specialized dosage forms of Hydrochlorothiazide that may not be available from other suppliers. While countries like China, Germany, and the United States also supply these formulations, Italy's emphasis on quality and innovation provides a competitive edge, making it a preferred source for Indian importers.

India imports Hydrochlorothiazide formulations from Italy due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Italian manufacturers provide products that meet international quality standards and offer formulations not produced domestically, fulfilling specific patient needs in India.

Compared to other suppliers like China, Germany, and the United States, Italy offers a competitive advantage in terms of product quality, innovation, and adherence to Good Manufacturing Practices (GMP). While other countries may offer lower prices, Italy's emphasis on quality and regulatory compliance makes it a preferred choice for Indian importers seeking reliable and high-quality Hydrochlorothiazide formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying suppliers, maintaining adequate inventory levels, and staying informed about regulatory updates.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain sufficient stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.
5. 5Regulatory Compliance: Stay updated on import regulations and ensure all necessary licenses and registrations are in place.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO using Form 40/41.
3. 3Import License: Apply for an Import License under the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): Obtain an NOC from the Ministry of Health and Family Welfare if required.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049079 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Provide batch-wise CoA for each shipment.
2. 2Certificate of Pharmaceutical Product (CoPP): Ensure the product is registered in Italy.
3. 3Good Manufacturing Practice (GMP) Certificate: Verify compliance with GMP standards